Thyroid nodule secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


== Overview ==
== Overview ==
[[Secondary prevention]] of a thyroid nodule is aimed at the [[Prevention (medical)|prevention]] of recurrence after removal of a primary nodule (specially in case of [[malignant]] lesions). Post-operative periodic monitoring with [[serum]] [[thyroglobulin]] levels, [[Radioactive iodine uptake|radioactive iodine scanning]], [[neck]] [[ultrasound]] and [[Thyroid-stimulating hormone|thyroid stimulating hormone]] ([[TSH]]) may decrease the chances of recurrence.


== Thyroid Nodule Secondary Prevention ==
== Thyroid Nodule Secondary Prevention ==
Secondary prevention of a thyroid nodule is aimed at the prevention of recurrence after removal of a primary nodule (specially in case of malignant lesions). The following steps outline the secondary prevention of malignant thyroid nodules:
[[Secondary prevention]] of a thyroid nodule is aimed at the [[Prevention (medical)|prevention]] of recurrence after removal of a primary nodule (specially in case of [[malignant]] lesions). The following steps outline the [[secondary prevention]] of [[malignant]] thyroid nodules:


=== 1. Routine screening for disease recurrence ===
=== 1. Routine screening for disease recurrence ===
* Measurement of serum thyroglobulin levels after total thyroidectomy.
* Measurement of [[serum]] [[thyroglobulin]] levels after [[Thyroidectomy|total thyroidectomy]].
* Post-op diagnostic RAI scanning
* Post-op diagnostic [[RAIU|radioactive iodine (RAI) scanning]]
* Post-op ultrasound
* Post-op [[neck]] [[ultrasound]]


=== 2. Serum TSH goals ===
=== 2. Serum TSH goals ===
* Maintain TSH levels between:
* Maintain [[Thyroid-stimulating hormone|TSH]] levels between:
** Non-stimulated thyroglobulin < 0.2 ng/ml : TSH should be 0.5-2.0 mU/L
** Non-stimulated [[thyroglobulin]] < 0.2 ng/ml : TSH should be 0.5-2.0 mU/L
** Non-stimulated thyroglobulin greater than equal to 0.2 ng/ml: TSH should be 0.1-0.5 mU/L
** Non-stimulated [[thyroglobulin]] greater than equal to 0.2 ng/ml: TSH should be 0.1-0.5 mU/L


=== 3. Evaluation of response to therapy ===
=== 3. Evaluation of response to therapy ===
* Serum thyroglobulin levels
* [[Serum]] [[thyroglobulin]] levels
* Neck ultrasound
* [[Neck]] [[ultrasound]]
* Whole body scanning (not routinely indicated)
* Whole body scanning (not routinely indicated)


=== 4a. Excellent response to therapy ===
=== 4a. Excellent response to therapy ===
* Primary follow-up with clinical exam and non-stimulated thyroglobulin levels (TSH goal 0.5-2 mU/L)
* Primary follow-up with clinical exam and non-stimulated [[thyroglobulin]] levels ([[Thyroid-stimulating hormone|TSH]] goal 0.5-2 mU/L)
* Non-stimulated thyroglobulin levels at 12-24 month intervals
* Non-stimulated [[thyroglobulin]] levels at 12-24 month intervals
* Periodic neck ultrasound
* Periodic [[neck]] [[ultrasound]]


== References ==
== References ==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 19:54, 1 November 2017

Thyroid nodule Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thyroid nodule from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thyroid nodule secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thyroid nodule secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thyroid nodule secondary prevention

CDC on Thyroid nodule secondary prevention

Thyroid nodule secondary prevention in the news

Blogs on Thyroid nodule secondary prevention

Directions to Hospitals Treating Thyroid nodule

Risk calculators and risk factors for Thyroid nodule secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Secondary prevention of a thyroid nodule is aimed at the prevention of recurrence after removal of a primary nodule (specially in case of malignant lesions). Post-operative periodic monitoring with serum thyroglobulin levels, radioactive iodine scanning, neck ultrasound and thyroid stimulating hormone (TSH) may decrease the chances of recurrence.

Thyroid Nodule Secondary Prevention

Secondary prevention of a thyroid nodule is aimed at the prevention of recurrence after removal of a primary nodule (specially in case of malignant lesions). The following steps outline the secondary prevention of malignant thyroid nodules:

1. Routine screening for disease recurrence

2. Serum TSH goals

  • Maintain TSH levels between:
    • Non-stimulated thyroglobulin < 0.2 ng/ml : TSH should be 0.5-2.0 mU/L
    • Non-stimulated thyroglobulin greater than equal to 0.2 ng/ml: TSH should be 0.1-0.5 mU/L

3. Evaluation of response to therapy

4a. Excellent response to therapy

References